Europe Adenomyosis Drugs Market, By Type (Diffuse, Nodular, Sclerotic, Adult Cystic, and Others), Treatment (Hormone Medication, Anti-Inflammatory Drugs, and Others), Patient Type (Adult, Geriatric, and Adolescence ), Dosage Form (Parenteral, Oral, Others), End User (Hospitals, Clinics, Specialty Center, Home Healthcare, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) - Industry Trends and Forecast to 2029.
Market Analysis and Insights
Adenomyosis is a benign uterine disorder in which endometrial glands and stroma are pathologically demonstrated in the myometrium. Women affected by adenomyosis may present with abnormal uterine bleeding (AUB), dysmenorrhea, dyspareunia, or infertility, but one-third of them are asymptomatic. Over the years, adenomyosis has remained a histopathological diagnosis made after hysterectomy in perimenopausal women with heavy menstrual bleeding (HMB) or pelvic pain. However, adenomyosis has also become a condition identified in young fertile-age women over the last decade because of the recent advancements in imaging techniques, even though a shared definition and classification are still lacking. Despite the improvement of diagnostic tools, the awareness of the condition is still poor.
The drugs used for the treatment of adenomyosis generally include anti-inflammatory drugs and hormonal drugs such as gonadotropin-releasing hormone analogs (Gnrh Analogs), estrogen-progestin, selective progesterone receptor modulators (SPRMs) or progestin, aromatase inhibitors, and gonadotropin-releasing hormone antagonist, among others. Some of these drugs are used to reduce adenomyotic lesion size and improve the patient's dysmenorrhea and quality of life.
The demand for adenomyosis drugs has increased more in developed countries. These countries had reimbursement policies for treatment along with the high prevalence of the disease and increasing healthcare expenditure. The market will grow in the forecasted period due to the exploration of emerging markets and increasing support of private and government agencies for treatment.
Europe adenomyosis drugs market report provides details of market share, new developments, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in ma
rket regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal. Strategic initiatives such as collaboration, agreement, and signing of sales agreements to invent and innovate pharmacological treatments are the major drivers which propelled the demand of the market in the forecast period.
Europe adenomyosis drugs market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the Europe adenomyosis drugs market will grow at a CAGR of 5.6% during the forecast period of 2022 to 2029.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Thousand, Pricing in USD
|
|
Segments Covered
|
By Type (Diffuse, Nodular, Sclerotic, Adult Cystic, and Others), Treatment (Hormone Medication, Anti-Inflammatory Drugs, and Others), Patient Type (Adult, Geriatric, and Adolescence ), Dosage Form (Parenteral, Oral, Others), End User (Hospitals, Clinics, Specialty Center, Home Healthcare, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)
|
|
Countries Covered
|
Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe
|
|
Market Players Covered
|
Mayne Pharma Group Limited, Accord Healthcare, Boehringer Ingelheim International GmbH, Ferring B.V., Par Pharmaceutical (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., among others.
|
Market Definition
Adenomyosis represents a unique pathophysiological condition in which normal-appearing endometrial mucosa resides within the myometrium and is thus protected from menstrual shedding. The resulting ectopic presence of endometrial tissue composed of glands and stroma is thought to affect normal contractile function and peristalsis of uterine smooth muscle, causing menometrorrhagia, infertility, and adverse obstetric outcomes. Adenomyosis imposes a substantial socioeconomic burden from increased medical care and loss of work productivity without mentioning the compromised quality of life.
Adenomyosis has a negative impact on women's quality of life in a high percentage of cases because of abnormal uterine bleeding and pain requiring a lifelong management plan through medical or surgical treatment. The choice depends on the woman's age, reproductive status, and clinical symptoms. However, the disease is increasingly diagnosed in young women with reproductive desire, and conservative treatments are preferred, such as hormonal medications.
Europe Adenomyosis Drugs Market Dynamics
Drivers
- High prevalence of adenomyosis disorders
Gynecologic disorders affect the female reproductive system. The most common symptoms of gynecologic disorders include pelvic pain, endometriosis, adenomyosis, abnormal vaginal bleeding, and breast pain and lumps, among others. The significance and severity of these symptoms often depend on age, as these symptoms may be related to hormonal changes that occur with aging.
With the increasing women population worldwide, the target population for female reproductive disorder has also increased. Adenomyosis, a gynecologic condition characterized by the presence of endometrial glands and stroma within the myometrium, can significantly reduce the lifestyle of an individual. Adenomyosis occurs in 8.8% to 61.5% of women undergoing hysterectomy, and rates vary widely by differences in diagnostic criteria and variations between and within pathologists. The prevalence is estimated to range from 20% to 34%, based on patients referred for pelvic imaging rather than the general population of women.
- Advancement in the diagnosis of adenomyosis
The development of imaging techniques, such as MRI and transvaginal ultrasonography (TVUS), has allowed clinicians to make a non-invasive diagnosis of adenomyosis in women also undergoing conservative treatments, identifying different phenotypes of the disease. After some attempts of histological classification, adenomyosis is classified into four subtypes according to MRI lesion localization in the inner or outer myometrium: intrinsic, extrinsic, intramural, and indeterminate.
Opportunity
- Increase demand for disease-specific drug treatment
According to pathogenic mechanisms, several medical hormonal and non-hormonal treatments are used off-label to manage pain and bleeding and to improve fertility outcomes. The use of GnRHa is indicated before fertility treatments to improve the chances of pregnancy in infertile women with adenomyosis, and the highest pregnancy rate is reported in those undergoing frozen embryo transfer after GnRHa pre-treatment. In contrast, the use of GnRHa for pain and bleeding should be considered only for short-term treatment because of menopausal effects. The levonorgestrel-releasing intrauterine system (LNG-IUS) is also an effective, reversible, and long-term treatment used successfully to treat adenomyosis. Results show that it reduces menstrual bleeding, pain, and uterine volume and has an overall satisfaction of 72%. However, new drugs, such as selective progesterone receptor modulators, aromatase inhibitors, valproic acid, and anti-platelet therapy, are under development for the treatment of adenomyosis.
Restraints/Challenges
The diagnostic tests for adenomyosis include highly technologically advanced products. The development of those products involves rigorous research and development by the developing player. Thus, the cost of the product remains high, which proportionally increases the cost of testing. The diagnostic tools and techniques used for the diagnosis of adenomyosis include ovarian endometrioma, adhesions, and deep nodular forms of the disease that often require ultrasonography or magnetic resonance imaging (MRI) to detect. Histologic verification, usually following surgical/laparoscopic visualization, can be useful in confirming the diagnosis, particularly for the most common superficial lesions.
The therapy of adenomyosis involves different stages and different procedures of treatment. Adenomyosis may be treated with surgery, hormonal drugs, anti-inflammatory drugs, etc. The diagnosis of adenomyosis is difficult, and this subsequently results in difficulty in the management of these patients, especially those who are asymptomatic but have a strong desire to preserve their uterus. Herbal drugs and home remedies are used as alternative therapies for the treatment of adenomyosis.
Recent Developments
- In October 2021, Debiopharm, a Swiss-based, Asia-Pacific biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, announced the Indonesian launch of triptorelin for the treatment of women with gynecological disorders, particularly adenomyosis, and its related diseases
- In September 2019, Professor Caroline Gargett and collaborators at the University of Queensland and Monash IVF were awarded a three-year USD 2.07 Million (AUD 3.05 Million) grant to determine the cause of adenomyosis and the physiological processes associated with the diseases
Europe Adenomyosis Drugs Market Divide
Europe adenomyosis drugs market is categorized into six notable segments which are based on type, treatment, patient type, dosage form, distribution channel, and end user . The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Diffuse
- Nodular
- Sclerotic
- Adult cystic
- Others
On the basis of type, the Europe adenomyosis drugs market is segmented into diffuse, nodular, sclerotic, adult cystic, and others.
Treatment
- Hormone medications
- Anti-inflammatory drugs
- Others
On the basis of treatment, the Europe adenomyosis drugs market is segmented into hormone medications, anti-inflammatory drugs, and others.
Patient Type
- Adolescence
- Adult
- Geriatric
On the basis of patient type, the Europe adenomyosis drugs market is segmented into adolescence, adult, and geriatric.
Dosage Form
- Parenteral
- Oral
- Others
On the basis of dosage form, the Europe adenomyosis drugs market is segmented into parenteral, oral, and others.
End User
- Hospitals
- Clinics
- Specialty center
- Home healthcare
- Ambulatory centers
- Others
On the basis of end user, the Europe adenomyosis drugs market is segmented into hospitals, clinics, specialty center, home healthcare, ambulatory centers, and others.
Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
- Others
On the basis of distribution channel, the Europe adenomyosis drugs market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.
Europe Adenomyosis Drugs Market Regional Analysis/Insights
Europe adenomyosis drugs market is analyzed, and market size insights and trends are provided by type, treatment, patient type, dosage form, distribution channel, and end user, as referenced above.
The countries covered in the Europe adenomyosis drugs market report are Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe.
Germany is expected to dominate the market during the forecast period due to the rising healthcare expenditure in the country.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing a forecast analysis of the country data.
Competitive Landscape and Europe Adenomyosis Drugs Market Share Analysis
Europe adenomyosis drugs market competitive landscape provides details of the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Europe adenomyosis drugs market.
Some of the key players in the market are Mayne Pharma Group Limited, Accord Healthcare, Boehringer Ingelheim International GmbH, Ferring B.V., Par Pharmaceutical (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe Vs. Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.
SKU-